Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 7Completed 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Breast Neoplasms 273Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 181Neoplasms 174Lung Neoplasms 137Multiple Myeloma 136Neoplasm Metastasis 101Colorectal Neoplasms 100Melanoma 87Ovarian Neoplasms 80Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 73Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Recurrence 56Urinary Bladder Neoplasms 55Hematologic Neoplasms 55Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 51Lymphoma, Follicular 48Glioblastoma 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Sarcoma 44

Interventions

Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Appendiceal Neoplasms × 90 days × Clear all
NCT05462717 2026-05-15

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled
GastrointestinalGynecologicThoracic

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
48 enrolled
Gastrointestinal

Appendiceal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡